Deep Origin Says Its Physics-Plus-AI Platform Hit Cancer Drug Targets 100 Times More Often Than Standard Machine Learning
Deep Origin said in August 2026 that its hybrid physics-and-AI drug discovery platform achieved a 31% hit rate against a cancer immunotherapy enzyme, nearly 100 times higher than typical machine-learning-only screening approaches.